ArticleDiscover oncology2026
Development and validation of a novel T cell exhaustion-related signature to predict prognosis in patients with breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most prevalent malignant tumor in women globally, with its prognosis linked to immune responses, especially CD8 + and CD4 + T cell infiltration. T cell exhaustion, an immune dysfunction seen in chronic infections and cancers, is not well understood in breast cancer. This study seeks to investigate the role and prognostic significance of genes related to T cell exhaustion in breast cancer through bioinformatics, offering insights into the mechanisms of T cell exhaustion in this disease.
methodsBreast cancer sample data from UCSC Xena and GEO databases underwent differential gene expression analysis with DESeq2. ssGSEA and WGCNA assessed T cell exhaustion-related genes. Key prognostic genes were identified through GO and KEGG analyses and PPI network construction. A prognostic model was developed using univariate Cox, Lasso regression, and multivariate Cox analyses, and its predictive performance was validated with an external dataset. Functional and immune infiltration characteristics of the prognostic genes were explored using GSEA and CIBERSORT.
resultsThe study identified 2,989 differentially expressed genes and 832 key module genes. Enrichment analysis indicated that these genes were associated with immune dysfunction and T cell exhaustion‑related pathways. A risk model was developed incorporating six prognostic genes: S100B, BCL2A1, RSPH1, KCNJ10, ZMYND10, and MOB3B. Using an appropriate cutoff, patients were stratified into low-risk and high-risk groups, with the overall survival (OS) curves of these groups exhibiting significant differences. The model's efficacy was validated using external datasets. Furthermore, the estimated IC50 values of multiple anticancer drugs showed differences between the two risk groups, warranting further investigation in the context of breast cancer therapy.
conclusionThis study uses bioinformatic analyses to highlight the prognostic importance and mechanisms of T cell exhaustion-related genes in breast cancer, offering insights for therapeutic targets that could enhance clinical management and immunotherapy strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.